Yeldos Serikbay
Yeldos Serikbay has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Aibol Terebay
Laboratory for Cell Biotechnology, Research Institute for Biological Safety Problems, National Holding QazBioPharm, Guardeyskiy 080409, Zhambyl Region, Kazakhstan
2 shared publications - Akbope Abdykalyk
Research Institute for Biological Safety Problems, National Holding QazBioPharm, LLP, Gvardeisky 080409, Kazakhstan
2 shared publications - Aktoty Anarbekova
Laboratory for Microbiology, Research Institute for Biological Safety Problems, National Holding QazBioPharm, Guardeyskiy 080409, Zhambyl Region, Kazakhstan
2 shared publications - Alinur Toleukhan
Research Institute for Biological Safety Problems
2 shared publications - Azamat Abdimukhtar
Laboratory for Microbiology, Research Institute for Biological Safety Problems, National Holding QazBioPharm, Guardeyskiy 080409, Zhambyl Region, Kazakhstan
2 shared publications - Aziz K. Nakhanov
Laboratory for Cell Biotechnology, Research Institute for Biological Safety Problems, National Holding QazBioPharm, Guardeyskiy 080409, Zhambyl Region, Kazakhstan
2 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1124
Phage-Derived Antimicrobial Strategies Against Treponema pallidum: Genomic Evidence, Biological Barriers, and Translational Roadmap
Syphilis is a systemic sexually transmitted infection caused by Treponema pallidum subsp. pallidum. Despite effective penicillin-based therapy, it remains a major public health challenge due to ongoing transmission, latent infection, congenital disease, and the lack of a licensed vaccine. While the resurgence of bacteriophage research has stimulated interest in alternative antimicrobials for sexually transmitted infections, direct extrapolation of classical lytic phage therapy to T. pallidum is premature. This pathogen is experimentally demanding, grows slowly, lacks validated lytic phages, and possesses an unusual outer membrane with sparse surface-exposed targets. However, comparative genomics has identified prophage-like elements in several Treponema species, while the T. pallidum-lineage genomes examined by Ridgway et al. did not contain detectable prophage regions. This shifts the rationale from endogenous T. pallidum prophage exploitation toward cautious evaluation of heterologous treponemal phage-derived modules, with cross-species target compatibility as a central requirement. This review critically evaluates phage-derived strategies against T. pallidum, discussing biological barriers, prophage genomics, candidate modalities, biosafety filters, and regulatory considerations. We propose a staged translational roadmap progressing from evidence appraisal and candidate prioritization to biochemical validation, direct T. pallidum testing, ex vivo assessment, in vivo validation, and product-class-specific development. Currently, the most credible outputs of this field are research tools, diagnostic binding modules, and early antimicrobial prototypes rather than clinical phage therapy for syphilis.
- 11 November 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (11) , 1124
Open AccessPhage-Derived Antimicrobial Strategies Against Treponema pallidum: Genomic Evidence, Biological Barriers, and Translational Roadmap
Syphilis is a systemic sexually transmitted infection caused by Treponema pallidum subsp. pallidum. Despite effective penicillin-based therapy, it remains a major public health challenge due to ongoing transmission, latent infection, congenital disease, and the lack of a licensed vaccine. While the resurgence of bacteriophage research has stimulated interest in alternative antimicrobials for sexually transmitted infections, direct extrapolation of classical lytic phage therapy to T. pallidum is premature. This pathogen is experimentally demanding, grows slowly, lacks validated lytic phages, and possesses an unusual outer membrane with sparse surface-exposed targets. However, comparative genomics has identified prophage-like elements in several Treponema species, while the T. pallidum-lineage genomes examined by Ridgway et al. did not contain detectable prophage regions. This shifts the rationale from endogenous T. pallidum prophage exploitation toward cautious evaluation of heterologous treponemal phage-derived modules, with cross-species target compatibility as a central requirement. This review critically evaluates phage-derived strategies against T. pallidum, discussing biological barriers, prophage genomics, candidate modalities, biosafety filters, and regulatory considerations. We propose a staged translational roadmap progressing from evidence appraisal and candidate prioritization to biochemical validation, direct T. pallidum testing, ex vivo assessment, in vivo validation, and product-class-specific development. Currently, the most credible outputs of this field are research tools, diagnostic binding modules, and early antimicrobial prototypes rather than clinical phage therapy for syphilis.
- Open Access
Bacteriophage-Based Therapeutics for Bacterial Sexually Transmitted Infections: From Biological Barriers to Translational Strategies
Bacterial sexually transmitted and sexually associated infections remain a major global health concern, increasingly complicated by antimicrobial resistance and the limited effectiveness of existing therapies. In this context, bacteriophage-based and phage-derived approaches have re-emerged as potential alternative antibacterial strategies. This narrative review examines their applicability across key bacterial pathogens associated with sexually transmitted infections, including Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Treponema pallidum and biofilm-associated bacterial vaginosis, with a particular focus on pathogen-specific biological barriers. Available evidence indicates that the success of phage-based interventions is strongly dependent on factors such as intracellular localisation, structural characteristics of the bacterial envelope and the presence of polymicrobial biofilms. While phage-derived platforms, including endolysins, depolymerases and engineered phages, demonstrate antibacterial activity in experimental settings, their effectiveness is uneven across different pathogens. Biofilm-associated infections appear more accessible to these approaches, whereas intracellular and structurally atypical bacteria are currently considered more challenging targets based on available mechanistic and experimental evidence. These observations highlight the need for pathogen-specific engineering strategies and delivery systems. Overall, phage-based therapeutics in this field should be considered within a framework that integrates biological constraints with targeted antimicrobial design.
Open AccessBacteriophage-Based Therapeutics for Bacterial Sexually Transmitted Infections: From Biological Barriers to Translational Strategies
Bacterial sexually transmitted and sexually associated infections remain a major global health concern, increasingly complicated by antimicrobial resistance and the limited effectiveness of existing therapies. In this context, bacteriophage-based and phage-derived approaches have re-emerged as potential alternative antibacterial strategies. This narrative review examines their applicability across key bacterial pathogens associated with sexually transmitted infections, including Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Treponema pallidum and biofilm-associated bacterial vaginosis, with a particular focus on pathogen-specific biological barriers. Available evidence indicates that the success of phage-based interventions is strongly dependent on factors such as intracellular localisation, structural characteristics of the bacterial envelope and the presence of polymicrobial biofilms. While phage-derived platforms, including endolysins, depolymerases and engineered phages, demonstrate antibacterial activity in experimental settings, their effectiveness is uneven across different pathogens. Biofilm-associated infections appear more accessible to these approaches, whereas intracellular and structurally atypical bacteria are currently considered more challenging targets based on available mechanistic and experimental evidence. These observations highlight the need for pathogen-specific engineering strategies and delivery systems. Overall, phage-based therapeutics in this field should be considered within a framework that integrates biological constraints with targeted antimicrobial design.